Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company
This article was originally published in Scrip
Shire plc and Baxalta Incorporated have confirmed they are to merge. The combined company, which will be 34% owned by Baxalta shareholders, will be "the partner of choice in rare diseases," claimed Shire CEO Flemming Ornskov.
You may also be interested in...
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
The $62.4bn price tag for Takeda’s acquisition of Shire is topped globally only by the Pfizer take-outs of Warner-Lambert and Wyeth, the merger that created GlaxoSmithKline, and Actavis’ purchase of Allergan.
Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.